<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2018.71007</article-id><article-id pub-id-type="publisher-id">HJO-24143</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20180100000_31536987.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  雷珠单抗注射液球内注射治疗糖尿病黄斑水肿与常规治疗方法对比观察
  A Comparative Study between Conventional Approaches and Intraocular Injection of Ranibizumab in the Treatment of Diabetic Macular Edema
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>边</surname><given-names>红霞</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>桦</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>边</surname><given-names>梦婷</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>瑞英</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>宓</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>学龙</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>淑清</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>凤鸣</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>国敏</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>永强</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>伟红</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>包头市眼科医院，内蒙古 包头</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>bianhongxia1966@163.com(边红)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>03</month><year>2018</year></pub-date><volume>07</volume><issue>01</issue><fpage>39</fpage><lpage>48</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探索更为有效，更为经济便捷的DME治疗手段。方法：分析2012年6月至2016年5月就诊于我院的DME患者经激光、玻璃体腔注射雷珠单抗/曲安奈德、玻璃体切割手术治疗的98例104只眼，其中男56例58只眼，女42例46只眼，平均年龄为57岁。结果：各组治疗前后视力和CMT变化情况：1) 玻璃体腔内注射TA，在治疗1月和3月时，患者视力有显著提高，CMT明显降低，差异有显著性(p = 0.000)；治疗6月视力稍有提高，CMT较治疗前变化不明显，差异无显著性。2) 玻璃体腔内注射雷珠单抗，在治疗1月时视力显著提高，CMT明显降低，差异有统计学意义(p = 0.001)；在治疗3月和6月时，视力略提高，CMT无明显变化，差异无显著性。3) 在接受黄斑区激光光凝和(或)全网膜光凝，视力在治疗1个月时，略下降，差异无显著性；视力在治疗3月和6月时，视力无变化，差异无显著性。CMT在治疗1月和3月时稍减轻，与治疗前无显著性差异；治疗6月时CMT明显减轻，差异有显著性(p = 0.001)。4) 在接受玻璃体切割术治疗1月、3月和6月时，视力均有所提高，差异有显著性(p = 0.001)。CMT在治疗1月时减轻，差异无显著性；在术后3月和6月时，CMT减轻，较治疗前差异有显著性(p = 0.001)。结论：玻璃体腔注射雷珠单抗和注射TA、黄斑区光凝与玻璃体切割术在治疗DME上都是有效的。在提高视力方面，注药和玻璃体切割术更为有效。玻璃体腔注射TA，效果亦较好，但并发白内障、继发青光眼、眼内炎等并发症较多，要权衡治疗效果与风险而慎重选择，对于严重白内障和人工晶体的患者亦不失为一种很好的选择。激光治疗如果作为首选，尽管视网膜水肿可以消退但视力提高不是很明显。玻璃体切割术效果稳定持久，但需要具备特定的手术条件和手术技术，需要掌握好适应症，可以作为治疗黄斑水肿的常见方法。 Purpose: The purpose of this research is to uncover a more effective, economical and more conve-nient approach in the treatment of diabetic macular edema (DME). Method: The research is con-ducted by analyzing 98 DME cases with 104 eyes that are treated through laser photocoagulation, intravitreal injection of Ranibizumab, intravitreal injection of triamcinolone (TA) and vitrectomy respectively in the Baotou Eye Hospital from June, 2012 to May, 2016. Among 98 cases with 104 eyes, 56 cases with 58 eyes are male patients while 42 cases with 46 eyes are female patients. The average age of 98 patients are 57. Results: The comparison of eyesight and central macular thick-ness (CMT) before and after treatment with different approaches: 1) In cases that are treated through intravitreal injection of TA, the effectiveness of this approach is significant in the first month and the third month. The eyesight of patients is considerably improved (p = 0.000). More-over, CMT of patients shows a remarkable decrease. However, the effectiveness of TA treatment is no longer significant in the third month and the sixth month. The eyesight of patients is slightly improved and CMT shows no remarkable change. 2) In cases that are treated through intravitreal injection of Ranibizumab, the effectiveness of this approach is statistically significant in the first month and the third month (p = 0.001). The eyesight of patients is considerably improved and CMT shows a remarkable decrease. Similarly, the effectiveness of Ranibizumab is no longer significant in the third month and the sixth month. The eyesight of patients is slightly improved and CMT shows no remarkable change. 3) In cases that are treated through laser photocoagulation in macular region or the whole retinal, the effectiveness of this approach is not significant since the first month. The eyesight of patients is slightly decreased. The effectiveness remained insignificant in the third and sixth month with no remarkable change of eyesight. CMT shows a slight decrease in the first and third month and manifests a statistically significant decrease in the sixth month (p = 0.001). 4) In cases that are treated through vitrectomy, the eyesight of patients is significantly improved in the first, third and sixth month. CMT shows a slight decrease in the first and third month but manifests a significant decrease in the sixth month when compared with the situation before treatment (p = 0.001). Conclusion: Laser photocoagulation, intravitreal injection of Ranibizumab, intravitreal injection of TA and vitrectomy are all effective in the treatment of DME. With respect to eyesight improvement, intravitreal injection and vitrectomy show more significant effectiveness. Although intravitreal injection of TA is considered to be more effective especially for patients with serious cataract or artificial lens when compared with other approaches, the risk of complications of cataract, secondary glaucoma or endophthalmitis is higher. Therefore, it is necessary to balance the effectiveness and potential complications when choosing different approaches. In terms of laser photocoagulation, it is effective to decrease CMT but shows no significant improvement of eyesight. In addition, the effectiveness of vitrectomy is more stable. However, it can only be implemented with specific operation conditions and skills. As a consequence, it can be applied as a conventional approach to treat DME. 
  
 
</p></abstract><kwd-group><kwd>糖尿病黄斑水肿，雷珠单抗，激光，玻璃体切割，曲安奈德, Diabetic Macular Edema</kwd><kwd> Ranibizumab</kwd><kwd> Laser Photocoagulation</kwd><kwd> Vitrectomy</kwd><kwd> Triamcinolone</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>雷珠单抗注射液球内注射治疗糖尿病黄斑水肿与常规治疗方法对比观察<sup> </sup></title><p>边红霞，杨桦，边梦婷，刘瑞英，郭宓，于学龙，王淑清，李凤鸣，马国敏，郭永强， 刘伟红</p><p>包头市眼科医院，内蒙古 包头</p><p>收稿日期：2018年3月5日；录用日期：2018年3月19日；发布日期：2018年3月26日</p><disp-formula id="hanspub.24143-formula126"><graphic xlink:href="//html.hanspub.org/file/7-2230181x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探索更为有效，更为经济便捷的DME治疗手段。方法：分析2012年6月至2016年5月就诊于我院的DME患者经激光、玻璃体腔注射雷珠单抗/曲安奈德、玻璃体切割手术治疗的98例104只眼，其中男56例58只眼，女42例46只眼，平均年龄为57岁。结果：各组治疗前后视力和CMT变化情况：1) 玻璃体腔内注射TA，在治疗1月和3月时，患者视力有显著提高，CMT明显降低，差异有显著性(p = 0.000)；治疗6月视力稍有提高，CMT较治疗前变化不明显，差异无显著性。2) 玻璃体腔内注射雷珠单抗，在治疗1月时视力显著提高，CMT明显降低，差异有统计学意义(p = 0.001)；在治疗3月和6月时，视力略提高，CMT无明显变化，差异无显著性。3) 在接受黄斑区激光光凝和(或)全网膜光凝，视力在治疗1个月时，略下降，差异无显著性；视力在治疗3月和6月时，视力无变化，差异无显著性。CMT在治疗1月和3月时稍减轻，与治疗前无显著性差异；治疗6月时CMT明显减轻，差异有显著性(p = 0.001)。4) 在接受玻璃体切割术治疗1月、3月和6月时，视力均有所提高，差异有显著性(p = 0.001)。CMT在治疗1月时减轻，差异无显著性；在术后3月和6月时，CMT减轻，较治疗前差异有显著性(p = 0.001)。结论：玻璃体腔注射雷珠单抗和注射TA、黄斑区光凝与玻璃体切割术在治疗DME上都是有效的。在提高视力方面，注药和玻璃体切割术更为有效。玻璃体腔注射TA，效果亦较好，但并发白内障、继发青光眼、眼内炎等并发症较多，要权衡治疗效果与风险而慎重选择，对于严重白内障和人工晶体的患者亦不失为一种很好的选择。激光治疗如果作为首选，尽管视网膜水肿可以消退但视力提高不是很明显。玻璃体切割术效果稳定持久，但需要具备特定的手术条件和手术技术，需要掌握好适应症，可以作为治疗黄斑水肿的常见方法。</p><p>关键词 :糖尿病黄斑水肿，雷珠单抗，激光，玻璃体切割，曲安奈德</p><disp-formula id="hanspub.24143-formula127"><graphic xlink:href="//html.hanspub.org/file/7-2230181x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/7-2230181x7_hanspub.png" /> <img src="//html.hanspub.org/file/7-2230181x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>糖尿病黄斑水肿(diabetic macular edema, DME)是糖尿病患者视力损害的重要原因 [<xref ref-type="bibr" rid="hanspub.24143-ref1">1</xref>] 。据国际糖尿病联盟(International Diabetes Federation, IDF)统计，2013年全球有3.82亿例糖尿病患者，糖尿病在全球的患病率很高，且处于快速增长阶段 [<xref ref-type="bibr" rid="hanspub.24143-ref2">2</xref>] 。中国是全球20~79岁糖尿病患者最多的国家，拥有9800万糖尿病患者 [<xref ref-type="bibr" rid="hanspub.24143-ref3">3</xref>] 。据我国各地区糖尿病视网膜病变(diabetic retinopathy, DR)流行病学调查文献资料 [<xref ref-type="bibr" rid="hanspub.24143-ref2">2</xref>] 和我国各地区糖尿病黄斑水肿(DEM)流行学调查文献资料 [<xref ref-type="bibr" rid="hanspub.24143-ref2">2</xref>] 显示，糖尿病黄斑水肿(DME)与临床有意义的黄斑水肿(clinical significant macular edema, CSME)在糖尿病罹患人群中的发病率分别为5.2% (3.1%~7.9%)和3.5% (1.9%~6.0%) [<xref ref-type="bibr" rid="hanspub.24143-ref4">4</xref>] 。从发病病程来看1型糖尿病病程超过5年的糖尿病患者出现DR的发病率为25%，超过10年者为60%，超过15年以上者高达80% [<xref ref-type="bibr" rid="hanspub.24143-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.24143-ref6">6</xref>] 。2型糖尿病5年以内病程者，使用胰岛素与不使用胰岛素治疗的患者中发生视网膜病变的比例为40%和24%，该比例在长达19年以上的患者中分别增加到84%和53%。2型糖尿病患者病程5年以下与25年以上发生增生型视网膜病变的比例分别为2%和25% [<xref ref-type="bibr" rid="hanspub.24143-ref6">6</xref>] 。</p><p>糖尿病黄斑水肿(DME)的发病率与血糖控制水平和糖尿病视网膜病变(DR)的严重程度均有关 [<xref ref-type="bibr" rid="hanspub.24143-ref7">7</xref>] ，视网膜病变越重，其发生率越高且DME可以发生在DR的任何时期，因此应加强对DR和DME的防治，探索其发病机理，寻找更为有效的治疗方法和更为经济便捷的治疗手段，一直是眼科临床工作的重点之一。目前治疗DME的主要方法是黄斑局限性或格栅样激光光凝或和全视网膜光凝、玻璃体腔注射曲安耐德(TA)以及玻璃体切除术，剥除或不剥除视网膜内界膜等常见方法。随着抗VEGF药物应用，雷珠单抗(Ranibizumab)商品名Lucentis，我国临床主要应用于老年黄斑变性(AMD)的治疗，应用其治疗DME是一种新方法，这种新方法与常见方法的对比尚缺乏临床大样本多中心研究。本研究收集、整理我院自2012年6月至2016年5月DME患者采用上述不同治疗方法行黄斑水肿治疗，通过测量视力和对黄斑OCT的观察，并行统计学分析，观察各自优缺点，加以对比研究，从而找出临床上更为安全、有效的治疗方法，更好地服务于临床，造福患者。</p></sec><sec id="s4"><title>2. 临床资料</title><p>分析2012年6月至2016年5月就诊于我院，明确诊断为DME的患者98例104眼，其中男56例58眼，女42例46眼，平均年龄为57岁。</p><sec id="s4_1"><title>2.1. 病例纳入标准</title><p>1) 糖尿病诊断明确，经眼科检查确诊为糖尿病视网膜病变的患者；</p><p>2) 眼底荧光血管造影FFA及OCT示黄斑区水肿；</p><p>3) 经国际标准视力表检查，最佳矫正视力 ≤ 0.4；</p><p>4) 屈光间质清；</p><p>5) 无青光眼及高眼压；</p><p>6) 无其它视网膜疾病、无影响疗效观察的其它眼病；</p><p>7) 治疗和随访过程中血糖控制稳定、空腹血糖 &lt; 8.0 mmol/L、无高血压及肾功能损害；</p><p>8) 黄斑区未行激光治疗、未接受视网膜或其它眼内手术者。</p></sec><sec id="s4_2"><title>2.2. 检查及方法</title><sec id="s4_2_1"><title>2.2.1. 视力</title><p>采用国际标准远近视力表检查患者最佳矫正中心视力并记录结果。</p></sec><sec id="s4_2_2"><title>2.2.2. 眼科检查</title><p>裂隙灯行前节和玻璃体、眼底检查。</p></sec><sec id="s4_2_3"><title>2.2.3. 眼压检查</title><p>采用喷气式眼压计连续测量三次取平均值。</p></sec><sec id="s4_2_4"><title>2.2.4. 光学相关相干断层扫描(OCT)检查仪器和方</title><p>散瞳后采用Topcon OCT进行黄斑中心凹视网膜厚度检查并测量其数值。</p></sec></sec><sec id="s4_3"><title>2.3. 病人资料</title><p>分析整理98例104眼DR患者发生DME，根据不同治疗方法分组。第1组行单纯玻璃体内注射TA3 mg (0.075 ml)共28例28眼。第2组行单纯玻璃体内注射雷珠单抗0.5 mg (0.05 ml)共32例34眼。第3组行单纯激光光凝共18例22眼。</p><p>第4组行玻璃体切割+激光光凝共20例20眼。</p></sec><sec id="s4_4"><title>2.4. 治疗方法</title><p>所有患者治疗前均被告知，TA或雷珠单抗或激光光凝治疗或玻璃体切除手术可能发生的并发症。手术前常规准备，所有手术均在手术室进行，按诊疗常规进行。</p></sec><sec id="s4_5"><title>2.5. 随访观察</title><p>所有小组注射结束后，术后1天、7天、2周、1月、3月及6月行视力、眼压、眼底检查，注意观察眼压和晶体混浊情况。对随诊过程中眼压高于21 mmHg的患者给予降眼压药物治疗。</p></sec><sec id="s4_6"><title>2.6. 统计分析</title><p>应用spss13.0统计软件进行分析。计量资料用x &#177; s表示，计算术前和术后各时间段视力、眼压、视网膜中央厚度CMT变化，同时，比较各治疗组视力和视网膜中央厚度CMT的差异，采用成组设计的t检验，对比两组治疗前后CMT变化，P &lt; 0.05作为差异有统计学意义的标准。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 一般资料</title><p>分析、整理符合纳入标准的糖尿病黄斑水肿患者98人104眼，其中男性62例，女性36例，随机分组，接受玻璃体腔注射TA患者28例28眼，男18例18眼，女10例10眼，平均年龄58.02 &#177; 10.8岁，平均视力0.15 &#177; 0.13，平均黄斑中心凹厚度(CMT) 566.31 &#177; 125.4 um，平均眼压14.133 &#177; 1.386 mmHg。接受玻璃体腔注射雷珠单抗治疗的患者32例34眼，男16例16眼，女16例18眼，平均年龄59.18 &#177; 6.1岁，0.12 &#177; 0.18，眼压15.28 &#177; 2.11 mmHg，平均黄斑中心凹厚度(CMT) 564.01 &#177; 123.5 um。接受黄斑区激光光凝患者18例22眼，男10例12眼，女8例10眼，平均年龄55.02 &#177; 8.08岁；视力0.21 &#177; 0.12，眼压14.21 &#177; 1.386 mmHg，黄斑中心凹厚度(CMT) 532.21 &#177; 121.54 um。接受玻璃体切割术患者20例20眼，男12例12眼，女8例8眼，平均年龄52.08 &#177; 8.05岁，视力0.12 &#177; 0.18，眼压14.12 &#177; 1.36 mmHg，平均黄斑中心凹厚度(CMT) 513.31 &#177; 121.4 um。</p></sec><sec id="s5_2"><title>3.2. 各组治疗前后视力变化情况</title><p>玻璃体腔内注射TA治疗前患者平均视力如表1所示，为0.15 &#177; 0.13，在治疗1月平均视力为0.41 &#177; 0.16(t = −7.664, p = 0.000)，治疗3个月平均视力为0.32 &#177; 0.13 (t = −6.238, p = 0.000)，患者视力有提高，差异有显著性；治疗6个月平均视力为0.20 &#177; 0.11 (t = −0.574, p = 0.093)，视力稍有提高，差异无显著性。</p><p>玻璃体腔内注射雷珠单抗治疗前患者平均视力如表1所示，为0.12 &#177; 0.18，在治疗1月时，平均视力为0.31 &#177; 0.22 (t = −7.004, p = 0.000)，治疗3月时平均视力0.21 &#177; 0.11 (t = −4.390, p = 0.001)，较1月时有视力有所回落，但仍较治疗前为好，差异有统计学意义；治疗6月时，平均视力为0.15 &#177; 0.18 (t = −0.439, p = 0.077)，与治疗前相比，视力略提高，差异无显著性。</p><p>在接受黄斑区激光光凝前平均视力如表1所示，为0.21 &#177; 0.12，治疗1月时，平均视力为0.18 &#177; 0.12 (t = −0.439, p = 0.767)，与治疗前相比患者视力略有下降，差异无显著性；在治疗3个月时，平均视力为0.25 &#177; 0.15 (t = −1.263, p = 0.432)，与治疗前相比，视力略有提升，差异无显著性；在治疗6个月时，平均视力为0.23 &#177; 0.16 (t = −1.251, p = 0.421)，与治疗前相比，视力无变化，差异无显著性。</p><p>在接受玻璃体切割术治疗前，平均视力如表1所示，为0.12 &#177; 0.18，在行玻璃体切割术后1个月时，平均视力为0.21 &#177; 0.19 (t = −4.125, p = 0.001)；术后3月时，平均视力为0.23 &#177; 0.18 (t = −4.213, p = 0.001)；术后6月时，平均视力为0.19 &#177; 0.17 (t = −3.891, p = 0.004)，与治疗前相比，视力均有所提高，差异有显著性。</p></sec><sec id="s5_3"><title>3.3. 各组治疗前后CMT变化情况</title><p>玻璃体腔注射TA治疗前CMT平均值如表2所示，为566.31 &#177; 125.4 um，治疗1月时，CMT为332.31 &#177; 94.66 um (t = 18.32, p = 0.030)，治疗3月时，CMT为289.44 &#177; 43.55 um (t = 10.85, p = 0.001)，视网膜中心厚度降低，差异有显著性；在治疗6个月时，CMT平均为441.23 &#177; 56.85 um (t = 14.31, p = 0.15)，视网膜中心厚度较治疗前变化不明显，差异无显著性。</p><p>玻璃体腔注射雷珠单抗治疗前，CMT平均值如表2所示，为564.01 &#177; 123.5 um，治疗1月时，CMT平均为386.50 &#177; 89.31 um (t = 16.12, p = 0.001)，与治疗前相比，视网膜中心厚度明显降低，差异有显著性；治疗3月时，CMT平均为441.32 &#177; 75.21 um (t = 13.21, p = 0.71)，治疗6月时，CMT平均为532.15 &#177; 112.31 um (t = 15.21, p = 0.98)，与治疗前相比，视网膜中心厚度无变化，差异无显著性。</p><p>在接受黄斑区激光光凝前CMT平均值如表2所示，为532.21 &#177; 121.54 um，治疗1月时，CMT平均值为462.31 &#177; 121.54 um (t = 13.25, p = 0.34)，治疗3月时，CMT平均为410.25 &#177; 113.21 um (t = 13.54, p = 0.35)，与治疗前相比，CMT减轻，差异无显著性；治疗6月时，CMT平均值为368.21 &#177; 121.31 um (t = 12.51, p = 0.001)，与治疗前相比，CMT水肿明显减轻，差异有显著性。</p><p>在接受玻璃体切除术治疗前，视网膜中央厚度平均值如表2所示，为513.31 &#177; 121.4 um，在行玻切术后1月，CMT为421.51 &#177; 121.32 um (t = 15.81, p = 0.12)，黄斑视网膜水肿减轻，较治疗前差异无显著性；在行玻切术后3月，CMT为452.31 &#177; 163.21 um (t = 16.31, p &lt; 0.005)，行玻切术后6月，CMT为398.21 &#177; 101.32 um (t = 16.21, p = 0.001)，黄斑视网膜厚度减轻，较治疗前差异有显著性。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Eyesight comparisons before and after the treatments of intravitreal injection of Ranibizumab, intravitreal injection of triamcinolone (TA), laser photocoagulation and vitrectom</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="3"  >治疗后</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >1个月</td><td align="center" valign="middle" >3个月</td><td align="center" valign="middle" >6个月</td></tr><tr><td align="center" valign="middle" >TA组</td><td align="center" valign="middle" >0.15 &#177; 0.13</td><td align="center" valign="middle" >0.41 &#177; 0.16 (t = −7.664, p = 0.000)</td><td align="center" valign="middle" >0.32 &#177; 0.13 (t = −6.238, p = 0.000)</td><td align="center" valign="middle" >0.20 &#177; 0.11 (t = −0.574, p = 0.093)</td></tr><tr><td align="center" valign="middle" >雷珠单抗组</td><td align="center" valign="middle" >0.12 &#177; 0.18</td><td align="center" valign="middle" >0.31 &#177; 0.22 (t = 7.004, p = 0.000)</td><td align="center" valign="middle" >0.21 &#177; 0.11 (t = −4.390, p = 0.001)</td><td align="center" valign="middle" >0.15 &#177; 0.18 (t = −0.439, p = 0.077)</td></tr><tr><td align="center" valign="middle" >黄斑部光凝</td><td align="center" valign="middle" >0.21 &#177; 0.12</td><td align="center" valign="middle" >0.18 &#177; 0.12 (t = −0.439，p = 0.767)</td><td align="center" valign="middle" >0.25 &#177; 0.15 (t = −1.263, p = 0.432)</td><td align="center" valign="middle" >0.23 &#177; 0.16 (t = −1.251, p = 0.421)</td></tr><tr><td align="center" valign="middle" >玻璃体切割术</td><td align="center" valign="middle" >0.12 &#177; 0.18</td><td align="center" valign="middle" >0.21 &#177; 0.19 (t = −4.125, p = 0.001)</td><td align="center" valign="middle" >0.23 &#177; 0.18 (t = −4.213, p = 0.001)</td><td align="center" valign="middle" >0.19 &#177; 0.17 (t = −3.891, p = 0.004)</td></tr></tbody></table></table-wrap><p>表1. 玻璃体腔注射雷珠单抗和注射TA、黄斑区光凝与玻璃体切割术治疗前后视力比较</p><p>以P &lt; 0.05为有显著性差异。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparisons of central macular thickness (CMT) before and after the treatments of intravitreal injection of Ranibizumab, intravitreal injection of triamcinolone (TA), laser photocoagulation and vitrectom</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="3"  >治疗后(um)</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >治疗前(um)</td><td align="center" valign="middle" >1个月</td><td align="center" valign="middle" >3个月</td><td align="center" valign="middle" >6个月</td></tr><tr><td align="center" valign="middle" >TA组</td><td align="center" valign="middle" >566.31 &#177; 125.4</td><td align="center" valign="middle" >332.31 &#177; 94.64 (t = 18.32, p = 0.030)</td><td align="center" valign="middle" >289.44 &#177; 43.55 (t = 10.85, p = 0.001)</td><td align="center" valign="middle" >441.23 &#177; 56.85 (t = 14.31, p = 0.15)</td></tr><tr><td align="center" valign="middle" >雷珠单抗组</td><td align="center" valign="middle" >564.01 &#177; 123.5</td><td align="center" valign="middle" >386.50 &#177; 89.31 (t = 16.12, p = 0.001)</td><td align="center" valign="middle" >441.32 &#177; 75.21 (t = 13.21, p = 0.71)</td><td align="center" valign="middle" >532.15 &#177; 112.31 (t = 15.21, p = 0.98)</td></tr><tr><td align="center" valign="middle" >黄斑区光凝</td><td align="center" valign="middle" >532.21 &#177; 121.54</td><td align="center" valign="middle" >462.31 &#177; 121.54 (t = 13.25, p = 0.34)</td><td align="center" valign="middle" >410.25 &#177; 113.21 (t = 13.54, p = 0.35)</td><td align="center" valign="middle" >368.21 &#177; 121.31 (t = 12.51, p = 0.001)</td></tr><tr><td align="center" valign="middle" >玻璃体切割术</td><td align="center" valign="middle" >513.31 &#177; 121.4</td><td align="center" valign="middle" >421.51 &#177; 121.32 (t = 15.81, p = 0.12)</td><td align="center" valign="middle" >452.31 &#177; 163.21 (t = 16.31, p &lt; 0.005)</td><td align="center" valign="middle" >398.21 &#177; 101.32 (t = 16.21, p = 0.001)</td></tr></tbody></table></table-wrap><p>表2. 玻璃体腔注射雷珠单抗和TA、黄斑区光凝与玻璃体切割术治疗前后视网膜中央厚度(CMT)比较</p><p>以P &lt; 0.05为有显著性差异。</p></sec><sec id="s5_4"><title>3.4. 其它方面变化</title><sec id="s5_4_1"><title>3.4.1. 眼压变化</title><p>TA治疗组，术后1月时，眼压平均值为20.31 &#177; 3.71 mmHg，较治疗前轻度上升，治疗3个月时，眼压平均值为23.51 &#177; 4.23 mmHg，治疗6个月时，眼压下降。雷珠单抗治疗组，在治疗术后1个月时，眼压平均值为15.32 &#177; 6.81 mmHg，在术后3月、6月时，眼压均无明显变化，在正常范围。在激光光凝组和玻切术组，治疗后1个月、3个月、6个月眼压无明显变化。</p></sec><sec id="s5_4_2"><title>3.4.2. 不良事件发生</title><p>在持续观察6个月中，四个治疗组均未发生眼内炎、视网膜脱离、玻血等玻璃体腔注射有关的并发症。白内障的发生在注药和激光手术治疗组均较术前有所增长，未见在注射TA组有明显白内障加重。</p></sec></sec></sec><sec id="s6"><title>4. 讨论</title><sec id="s6_1"><title>4.1. 糖尿病黄斑水肿(DME)是影响糖尿病视网膜病变患者视力的主要原因之一</title><p>DME的病理学过程相当复杂，是一个多因素作用的结果，目前，研究证实主要有两大因素：一是内环境的改变。高血糖导致血液系统的变化，视网膜缺血、缺氧，眼内炎症因子浓度改变，血管内皮生长因子浓度升高可以导致血管内皮失代偿，白细胞因子粘附；色素上皮衍生因子浓度下降，蛋白激酶C产物增加会引起血视网膜屏障的破坏 [<xref ref-type="bibr" rid="hanspub.24143-ref8">8</xref>] ，血管通透性增加，黄斑区视网膜内层液体的积聚；高血糖引起细胞内葡萄糖浓度升高，自由基形成，蛋白激酶C激活 [<xref ref-type="bibr" rid="hanspub.24143-ref9">9</xref>] ；高血糖可以导致高级糖基化终产物形成(AGEs, Advanced Glycation End products) [<xref ref-type="bibr" rid="hanspub.24143-ref10">10</xref>] ，研究发现，AGEs浓度升高与眼内炎症因子浓度的变化直接相关 [<xref ref-type="bibr" rid="hanspub.24143-ref11">11</xref>] 。从而导致视网膜神经血管的损伤和糖尿病视网膜病变和黄斑水肿的进展。第二是物理学因素。玻璃体视网膜界面的改变在糖尿病黄斑水肿的形成过程中也是有一定的作用 [<xref ref-type="bibr" rid="hanspub.24143-ref12">12</xref>] 。玻璃体后脱离不完全时对于黄斑区视网膜的牵拉是引起黄斑水肿的重要作用之一。</p></sec><sec id="s6_2"><title>4.2. 目前，对于糖尿病黄斑水肿的治疗主要有以下几种方法</title><p>局部视网膜光凝或格子样光凝，激光光凝治疗弥散性黄斑水肿，激光光斑覆盖整个荧光素渗漏区，目的使阻值或减少异常血管渗漏，促进黄斑水肿和渗出的吸收 [<xref ref-type="bibr" rid="hanspub.24143-ref13">13</xref>] 。EDTRS (Early Treatment Diabetic Retinopathy Study)研究指出，在视网膜增厚或者硬性渗出累及或趋向于黄斑中心凹，并且视力大于0.01的患者，联合应用局部光凝和格子样光凝将视力丧失的危险降低了50% [<xref ref-type="bibr" rid="hanspub.24143-ref14">14</xref>] 。EDTRS研究组推荐EDTRS研究组推荐对于合并黄斑水肿的轻度、对于合并黄斑水肿的轻度、中度非增殖期糖尿病患者采用格栅光凝或直接局部光凝治疗渗漏的微血管瘤，对于严重的非增殖期和所有增殖期糖尿病视网膜病变患者采用全视网膜激光光凝联合局部光凝的办法来治疗。</p><p>激光治疗有它的并发症，如中心视力丧失、玻璃体出血、对比敏感度降低、由于激光疤痕引起的视野中心暗点、色觉损害和头痛 [<xref ref-type="bibr" rid="hanspub.24143-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.24143-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.24143-ref17">17</xref>] 。</p><p>本研究在激光治疗组中，随访1个月时，视力提高不明显，在随访3个月、6个月时，激光治疗在视力提高方面有改善，但与治疗前相比无统计学意义。在黄斑区视网膜厚度消退方面，6个月组较3个月组和1个月组改善明显，且随着6个月时，黄斑水肿消退与治疗前相比有显著意义。</p><p>激光对于局部黄斑水肿疗效较好，但对于弥漫性黄斑水肿，无论从解剖学角度还是从功能角度，治疗效果都不近人意。即使采取多次激光治疗，弥散性黄斑水肿对于激光治疗的反应依然较差。随着随访时间的延长，可以看到并发症相继出现：由于激光导致视网膜外层瘢痕形成，视网膜色素上皮萎缩，这一情况如果发生在黄斑中心凹下就可以导致视力显著下降；同时过度激光引起的视网膜下纤维增殖也导致视力下降。因此，尽管格栅光凝对于弥散性黄斑水肿能取得一定疗效，但在科学飞速发展的今天，这种治疗方法所取得的疗效以不能让医生和患者满意。</p><p>玻璃体腔内注药是治疗对于光凝不敏感的DME的有效手段 [<xref ref-type="bibr" rid="hanspub.24143-ref18">18</xref>] 。目前，用于玻璃体腔注射治疗糖尿病黄斑水肿的药物有两类：一类为皮质类固醇类药物，另一类为抗血管内皮生长因子。一直以来玻璃体腔注射的皮质类固醇类药物主要为曲安奈德，这类药物可以减轻炎症反应和血管渗漏，Gillies [<xref ref-type="bibr" rid="hanspub.24143-ref19">19</xref>] Ockrim等 [<xref ref-type="bibr" rid="hanspub.24143-ref20">20</xref>] 报道。本研究在注射曲安耐德组中，视力有改善，视网膜厚度减轻，但有5例患者在治疗后20天出现高眼压，经药物治疗及密切随访2个月后眼压恢复，有1例出现白内障加重，无一例发生眼内炎、球内出血及视网膜脱离等并发症。</p><p>血管内皮生长因子(VEGF)当血糖升高，视网膜处于缺血缺氧状态时升高，导致血视网膜屏障破坏，血管通透性增加，视网膜黄斑区水肿。目前雷珠单抗(Ranibizumab)商品名lucentis，能对抗所有VEGF的异构体并已经被美国FDA批准认证。一直以来，还未见大规模随机对照的临床试验用于DME的治疗，仅有一些小的病例报道 [<xref ref-type="bibr" rid="hanspub.24143-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.24143-ref22">22</xref>] 。雷珠单抗自2012年引入我国，主要用于湿性老年性黄斑病变的治疗，将雷珠单抗用于治疗DR中DME，尚属新的治疗方法，缺乏我国大样本多中心研究，缺乏与治疗DME常规方法对比。本研究共32例34眼中，在视力方面，注射一针在治疗1个月后视力明显改善，3个月明显回褪，在治疗6个月后视力恢复到治疗前。在黄斑区视网膜厚度方面，治疗1个月时，水肿改善最明显，3个月次之，6个月恢复到治疗前。所有注射雷珠单抗患者无一例严重并发症发生。</p><p>在注射组中，我们注意到有的少数患者在注射后黄斑区视网膜厚度恢复而视力没有改善。Gibran等 [<xref ref-type="bibr" rid="hanspub.24143-ref23">23</xref>] 认为对于OCT上内层视网膜具有较高反射的患者，治疗后视力提高的希望较大，反之可能视网膜神经上皮已经萎缩，视力恢复的机会较小。</p><p>玻璃体视网膜手术对于部分患者是唯一可行的阻止永久视力损害的选择，没有后脱离的玻璃体后皮质对于黄斑部的牵拉在糖尿病黄斑水肿的形成过程中具有重要作用，因此，对于存在牵拉因素的糖尿病黄斑水肿采取玻璃体切割来治疗，可以取得一定疗效 [<xref ref-type="bibr" rid="hanspub.24143-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.24143-ref25">25</xref>] 。然而对于没有牵拉因素的患者采取玻璃体切割的方法也具有一定的疗效 [<xref ref-type="bibr" rid="hanspub.24143-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.24143-ref27">27</xref>] ，其原因在于玻璃体切除的同时也降低了眼内导致血管通透性增加的细胞因子以及血管内皮生长因子的浓度。Yamamoto [<xref ref-type="bibr" rid="hanspub.24143-ref28">28</xref>] 和Shimmonagano [<xref ref-type="bibr" rid="hanspub.24143-ref29">29</xref>] 报道的两项回顾性研究表明应用玻璃体切割治疗糖尿病黄斑水肿取得了良好的疗效，黄斑厚度减少，最佳矫正视力提高，且随访两年，保持不变。在我们的研究中，行玻璃体切割术患者20例20眼，在随访1月、3月、半年中，视力均有明显提高，且与治疗前相比有统计学意义。在黄斑区水肿方面，随访1月、3月、半年中，视网膜水肿明显改善，尤其在随访半年时，黄斑水肿和视力改善均很明显。手术过程中无一例发生术后网脱、网膜出血等并发症，仅在2例患者术后治疗发生了白内障加重。</p><p>在临床中每种治疗方法和手段都有其优缺点，每位患者都有各自的具体条件和情况，何种治疗手段才能给患者带来最大益处，使患眼视力提高或避免进一步视力损害，这就需要临床医生探索更好的治疗方案或何种组合来使患者受益，是每位临床工作者的追求。</p></sec></sec><sec id="s7"><title>5. 结论</title><p>玻璃体腔注射雷珠单抗和注射TA、黄斑区光凝与玻璃体切割术的治疗都是有效的，但是，在提高视力方面，注药和玻璃体切割术更为有效，玻璃体腔注射雷珠单抗在提高视力方面效果肯定，作用明显，副作用小，但需要反复注射次数多，且价格昂贵。玻璃体腔注射TA，效果亦较好，但并发白内障、继发青光眼、眼内炎等并发症较多，所以，要权衡治疗效果与风险而慎重选择，考虑其价格较低，对于贫困病人及有原发性白内障的病人亦不失为一种很好的选择。激光治疗如果作为首选，尽管视网膜水肿可以消退但视力提高不是很明显，建议在注药消退黄斑水肿后给以适量激光光凝。玻璃体切割术效果稳定持久，但需要具备特定的手术条件和手术技术，需要掌握好适应症，并熟练掌握玻璃体切割技术，可以作为治疗黄斑水肿的常见方法，但该方法技术难度大，费用较高。</p></sec><sec id="s8"><title>6. 展望(存在问题)</title><p>在DME诊断中，目前研究都集中在黄斑中心凹视网膜厚度增加的患者，忽略了水肿尚未累及中心凹的部分患者，这就造成了统计资料上的部分漏诊。</p><p>在随访观察中，有部分病例随诊期限较短而未纳入，有部分资料遗漏，要做好健康教育工作，增加患者依从性。</p><p>样本量在部分治疗组较少，会因例数较少而产生样本偏倚，需在工作中增大样本量。</p></sec><sec id="s9"><title>文章引用</title><p>边红霞,杨 桦,边梦婷,刘瑞英,郭 宓,于学龙,王淑清,李凤鸣,马国敏,郭永强,刘伟红. 雷珠单抗注射液球内注射治疗糖尿病黄斑水肿与常规治疗方法对比观察A Comparative Study between Conventional Approaches and Intraocular Injection of Ranibizumab in the Treatment of Diabetic Macular Edema[J]. 眼科学, 2018, 07(01): 39-48. https://doi.org/10.12677/HJO.2018.71007</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.24143-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Iklein, R., Klein, B.E. and Moss, S.E. (1991) The Epidemiology of Ocular Problems in Diabetes Mellitus. Blackwell Scientific Pub-lications, Boston, 1-51.</mixed-citation></ref><ref id="hanspub.24143-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会眼科学会眼底病学组黎晓新, 等. 我国糖尿病视网膜病变临床诊疗指南（2014年） [J]. 中华眼科杂志, 2014, 50(11): 851-865.</mixed-citation></ref><ref id="hanspub.24143-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">International Diabetes Federation. IDF Diabetes Atlas. 6th Edition, International Diabetes Federation, Brussels, Belgium.</mixed-citation></ref><ref id="hanspub.24143-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wang, F.H., Liang, Y.B., Zhang, F., et al. (2009) Prevalence of Diabetic Retinopathy in Rural China: The Handan Eye Study. Ophthalmology, 116, 461-467. https://doi.org/10.1016/j.ophtha.2008.10.003</mixed-citation></ref><ref id="hanspub.24143-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Klein, R., Klein, B.E, Moss, S.E., et al. (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy II. Prevalence and Risk of Diabetic Relinopathy When Age at Diagnosis Is Less Than 30 Years. Arch Ophthalmology, 102, 520-526. https://doi.org/10.1001/archopht.1984.01040030398010</mixed-citation></ref><ref id="hanspub.24143-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Varma, R., Torres, M., Pena, F., et al. (2004) Prevalence of Di-abetic Retinapathy in Adult Lations: The Los Angeles Latino Eye Study. Ophthalmology, 111, 1298-1306. https://doi.org/10.1016/j.ophtha.2004.03.002</mixed-citation></ref><ref id="hanspub.24143-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Malik, R.A., Lic, A.W., et al. (2005) Elevated Plasma CD 105 and Vitreous VEGF Levels in Diabetic Retinopathy. Journal of Cellular and Molecular Medicine, 9, 692-697. https://doi.org/10.1111/j.1582-4934.2005.tb00499.x</mixed-citation></ref><ref id="hanspub.24143-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Do Carmo, A., Ramos, P., Reis, A., et al. (1998) Breakdown of the Inner and Outer Blood Retinal Barrier in Streptozotocin-Induced Diabetes. Experimental Eye Research, 67, 569-575. https://doi.org/10.1006/exer.1998.0546</mixed-citation></ref><ref id="hanspub.24143-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Witmer, A.N., Vrensen, G.F., Van Noorden, C.J., et al. (2003) Vascular Endothelial Growth Factors and Angiogenesis in Eye Disease. Progress in Retinal and Eye Research, 22, 1-29. https://doi.org/10.1016/S1350-9462(02)00043-5</mixed-citation></ref><ref id="hanspub.24143-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ramasamy, R., Vannucci, S.J., Yam, S.S., et al. (2006) Advanced Glyca-tion End Products and RAGE: A Common Thread in Aging, Diabetes Neurodegeneration, and Inflammation. Ophthalmology, 113, 1706-1712.</mixed-citation></ref><ref id="hanspub.24143-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kim, W., Hudson, B.I., Moser, B., et al. (2005) Receptor for Advanced Glycation End Products and Its Ligands: A Journey from the Complication of Diabetes to Its Pathogenesis. Ann NY Acad Sci, 1043, 553-561.  
https://doi.org/10.1196/annals.1338.063</mixed-citation></ref><ref id="hanspub.24143-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Harbour, J.W., Smiddy, W.E., Flynn, H.W.J., et al. (1996) Vitrectomy for Diabetic Macular Edema Associated with a Thickened and Taut Posterior Hyaloidsmembrane. American Journal of Ophthalmology, 121, 405-413.  
https://doi.org/10.1016/S0002-9394(14)70437-4</mixed-citation></ref><ref id="hanspub.24143-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Porta, M.S. and Banadello, F. (1987) Diabetic Retinopathy Study Research Group Photocoagulation for Diabetic Macular Edema: Early Treatment Diabetic Retinopathy Study Report NO. 4. International Ophthalmology Clinics, 27, 265-272. https://doi.org/10.1097/00004397-198702740-00006</mixed-citation></ref><ref id="hanspub.24143-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yamanoto, T., Takeuchi, S., Sato, Y. and Yamashita, H. (2007) Long-Term Follow-Up Results of Pars Plana Vitrectomy for Diabetic Macular Edema. Jpn J Ophthalmol, 51, 285-291.</mixed-citation></ref><ref id="hanspub.24143-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Americar Diabetes Association (2002) Diabetic Retinopathy. Diabetes Care, 25, 590-593.</mixed-citation></ref><ref id="hanspub.24143-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kohner, E.M. (1993) Fortnightly Review: Diabetic Retinopathy. BMJ, 307, 1195-1199.  
https://doi.org/10.1136/bmj.307.6913.1195</mixed-citation></ref><ref id="hanspub.24143-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hansson-lundblad, C., Holm, K., Agardh, C.D., et al. (2002) A Small Number of Older Type 2 Diabetic Patients End up Visuslly Impaired Despite Regular Photographic Screening and Laser Treatment for Diabetic Retinopathy. Acta Ophthalmol Scand, 80, 310-315. https://doi.org/10.1034/j.1600-0420.2002.800315.x</mixed-citation></ref><ref id="hanspub.24143-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Martidis, A., Duker, J.S., Greenberg, P.B., et al. (2002) Intravitreal Triamcinolone for Refractory Diabetic Macular Edema. Ophthalmology, 109, 920-927. https://doi.org/10.1016/S0161-6420(02)00975-2</mixed-citation></ref><ref id="hanspub.24143-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Gillies, M.C., Sutter, F.K., Simpon, J.M., et al. (2006) Intravitreal Triamcinolone for Refractory Diabetic Macular Edema: Two-Year Results of a Double-Masked, Plracebocontrolled, Randomized Clinical Trial. Ophthalmology, 113, 1533-1538. https://doi.org/10.1016/j.ophtha.2006.02.065</mixed-citation></ref><ref id="hanspub.24143-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ockrim, I.K., Senswathi, S., Falk, S., et al. (2006) A Randomized Trial of Intravitreal Triamcinolone versus Macular Oedema Invest Ophthalmol Vis Sci, 47, 5438.</mixed-citation></ref><ref id="hanspub.24143-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Chun, D.W., Heier, J.S., Tpopping, T.M., et al. (2006) A Pilot Study of Mukltiple Intravitreal Injections of Ranibizumab in Patients with Center-Involving Clinically Significant Diabetic Macular Edema. Ophthalmology, 113, 1706-1712. https://doi.org/10.1016/j.ophtha.2006.04.033</mixed-citation></ref><ref id="hanspub.24143-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Nguyen, Q.D., Tatlipinar, S., Shah, S.M., et al. (2006) Vascularendothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema. American Journal of Ophthalmology, 142, 961-969.  
https://doi.org/10.1016/j.ajo.2006.06.068</mixed-citation></ref><ref id="hanspub.24143-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Gibran, S.K., Khan, K., Jungkim, S. and Cleary, P.E. (2007) Optical Coherence Tomographic Pattern May Predict Visual Outcome after Intravitreal Triamcinolone for Diabetic Macular Edema. Ophthalmology, 114, 890-894.  
https://doi.org/10.1016/j.ophtha.2006.11.026</mixed-citation></ref><ref id="hanspub.24143-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Gandorfer, A., Messmer, E.M., UIbig, M.W., et al. (2000) Resolution of Diabetic Macular Edema after Surgical Removal of the Posterior Hyaloid and the Inner Limiting Membrane. Retina, 20, 126-133.  
https://doi.org/10.1097/00006982-200002000-00004</mixed-citation></ref><ref id="hanspub.24143-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Mochizuki, Y., Hata, Y., Enaida, H., et al. (2006) Evalualting Ad-junctive Surgical Procedures during Vitrectomy for Diabetic Macular Edema. Retina, 26, 143-148. https://doi.org/10.1097/00006982-200602000-00003</mixed-citation></ref><ref id="hanspub.24143-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Yanyali, A., Horozoglu, F., Celik, E., et al. (2007) Long-Term Out-comes of Pars Plana Vitrectomy with Internal Limiting Membrane Removal in Diabeyic Macular Edema. Relina, 27, 557-566.</mixed-citation></ref><ref id="hanspub.24143-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Patel, J.I., Hykin, P.G., Schadt, M., et al. (2006) Pars Plana Vitrectomy for Diabetic Macular Edema: OCT and Func-tional Correlations. Eye, 20, 674-680. https://doi.org/10.1038/sj.eye.6701945</mixed-citation></ref><ref id="hanspub.24143-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Yamanoto, T., Takeuchi, S., Sato, Y. and Yamashita, H. (2007) Long-Term Follow-Up Results of Pars Plana Vitrectomy for Diabetic Macular Edema. Japanese Journal of Ophthalmology, 51, 285-291. 
https://doi.org/10.1007/s10384-007-0448-z</mixed-citation></ref><ref id="hanspub.24143-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Shimomagano, Y., Makiuchi, R., Miyazaki, M., Ethimomagano, Y., Makiuchi, R., Miyazaki, M., et al. (2007) Results of Visual Acuity and Foveal Thickness in Diabetic Macular Edema after Vitrectomy. Japanese Journal of Ophthalmology, 51, 204-209. https://doi.org/10.1007/s10384-007-0423-8</mixed-citation></ref></ref-list></back></article>